TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03723447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/epinephrine/dexamethasone
Description: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
Study: NCT02619422

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive cardiac rehabilitation program in less time
Description: 2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
Study: NCT01606878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02026570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal Focus of Attention
Description: Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
Study: NCT00592683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aripiprazole
Description: tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 1600mg (4 capsules) daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03804983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control-IQ with MyTDI
Description: Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
Study: NCT00139113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
Study: NCT02317510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined anesthesia
Description: Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: General anesthesia for laparoscopic cholecystectomy
Study: NCT03456115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical nasal dilator
Description: Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
Study: NCT01392833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
Study: NCT02216565

Intervention type: OTHER
Group type: OTHER
Intervention: Hospitalization in specialized neuro-vascular unit

Intervention type: OTHER
Group type: OTHER
Intervention: Hospitalization in specialized neuro-vascular unit

Intervention type: DRUG
Group type: OTHER
Intervention: Alteplase if patient is eligible
Description: Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)

Intervention type: DRUG
Group type: OTHER
Intervention: Alteplase if patient is eligible
Description: Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
Study: NCT00139113

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
Study: NCT02216565

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular treatment
Description: Recanalization treatment (thrombectomy / intraarterial thrombolysis)
Study: NCT01814657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine hydrochloride (HCl) 1% solution
Description: Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline%
Description: Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
Study: NCT01122927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
Study: NCT00139113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
Study: NCT03480321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 mg
Description: One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMR 150 mg
Description: Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMR 200 mg
Description: Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
Study: NCT02132663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Marketed routine infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An investigational infant formula containing an alternate source of DHA
Study: NCT02281591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: Tablets containing 900 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-licarbazepine
Description: capsules containing 225 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-licarbazepine
Description: capsules containing 225 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-licarbazepine
Description: capsules containing 225 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-licarbazepine
Description: capsules containing 225 mg
Study: NCT03141671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiation
Description: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiation
Description: Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study: NCT02026570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Focus of Attention
Description: Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
Study: NCT04689438

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid
Description: GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid
Description: GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid
Description: GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
Study: NCT01887093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Description: Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Description: Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
Study: NCT03615508

Intervention type: DRUG
Group type: OTHER
Intervention: 10% phenylephrine
Description: 10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
Study: NCT03473548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable sleep monitor
Description: Type III at home portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory Polysomnography
Description: Polysomnography testing will determine the sleep stages, apnea hypopnea index (AHI), blood saturation oxygen nadir (SPO2 nadir), and average blood oxygen saturation. A McGill Oximetry Score will also be calculated for the in-laboratory PSG.
Study: NCT04093063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-stellated Icosahedron
Description: A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
Study: NCT02192840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty with stent implantation
Description: Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty with stent implantation
Description: Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
Study: NCT02380690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach Assignment
Description: Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
Study: NCT01585584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
Study: NCT00727532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg by mouth twice daily for 28 consecutive days
Study: NCT00829933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b tablets
Description: DU-176b tablets taken once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b tablets
Description: DU-176b tablets taken once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b tablets
Description: DU-176b tablets taken once daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin potassium tablets
Description: Warfarin potassium tablets taken once daily for up to 12 weeks
Study: NCT03551262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTSC
Description: Positioning of OTSC in bleeding peptic ulcer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTS clip
Description: Positioning of TTS clip in bleeding peptic ulcer
Study: NCT01844167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Noxipoint Therapy (NT)
Description: • For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical therapy(PT)
Description: •Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
Study: NCT00004190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT00306111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Single dose (6mg) one day after chemotherapy
Study: NCT01804829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Civacir® 10%
Description: The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Civacir® 10%
Description: The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
Study: NCT03961477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential therapy
Description: Exercise therapy
Study: NCT01138943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthodont
Description: 15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soludent
Description: 15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse
Study: NCT02788162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
Study: NCT00088205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 500 milligrams (mg), oral, daily, up to six 28-day cycles
Study: NCT00988351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: continuous positive airway pressure determined by polysomnography titration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-adjusting positive airway pressure treatment
Description: Pressure range 4-18 centimeters of water (cm H2O)
Study: NCT02587689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MUC1 CAR T Cells
Study: NCT01654237

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: questionnaires
Description: 185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
Study: NCT02430922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iVolution nitinol stent
Study: NCT05575115

Intervention type: BEHAVIORAL
Intervention: Peer Comparison
Description: Peer comparison was an email-based intervention. Clinicians were ranked from highest to lowest inappropriate prescribing rate within each region using EHR data. Clinicians with the lowest inappropriate prescribing rates (the top-performing decile) were told via monthly email they were Top Performers. The remaining clinicians were told that they were Not a Top Performer in an email that included the number and proportion of antibiotic prescriptions they wrote for antibiotic-inappropriate acute respiratory tract infections, compared with the proportion written by top performers.
Study: NCT03806946

Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalography
Description: diagnosis epileptic discharge

Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalography
Description: diagnosis epileptic discharge
Study: NCT01661257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Study: NCT01850615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administrated subcutaneously (s.c., under the skin) at each main meal.
Study: NCT03806946

Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalography
Description: diagnosis epileptic discharge
Study: NCT01850615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin
Description: Administrated subcutaneously (s.c., under the skin) once daily.
Study: NCT01850615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin
Description: Administrated subcutaneously (s.c., under the skin) once daily.
Study: NCT02209506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126 Matched Placebo
Description: MLN3126 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126 Matched Placebo
Description: MLN3126 placebo-matching tablets
Study: NCT05886361

Intervention type: OTHER
Intervention: No intervention involved
Description: No intervention involved

Intervention type: OTHER
Intervention: No intervention involved
Description: No intervention involved

Intervention type: OTHER
Intervention: No intervention involved
Description: No intervention involved
Study: NCT01968941

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiotherapy (CRT)
Study: NCT03578679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Oral Product
Description: treatment of pediculosis (head lice)